CA2402247A1 - Biodegradable immunomodulatory formulations and methods for use thereof - Google Patents
Biodegradable immunomodulatory formulations and methods for use thereof Download PDFInfo
- Publication number
- CA2402247A1 CA2402247A1 CA002402247A CA2402247A CA2402247A1 CA 2402247 A1 CA2402247 A1 CA 2402247A1 CA 002402247 A CA002402247 A CA 002402247A CA 2402247 A CA2402247 A CA 2402247A CA 2402247 A1 CA2402247 A1 CA 2402247A1
- Authority
- CA
- Canada
- Prior art keywords
- microcarrier
- complex
- imp
- sequence
- pyrimidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Abstract
The invention provides new compositions and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMP/MC) complexes. The IMP/MC complexes may be covalently or non-covalently bound, and feature a polynucleotide comprising at least one immunostimulatory sequence bound to a biodegradable microcarrier or nanocarrier.
Claims (71)
1. An immunomodulatory polynucleotide/microcarrier (IMP/MC) complex, comprising:
a polynucleotide comprising an immunostimulatory sequence (ISS) linked to a biodegradable microcarrier (MC), wherein the ISS comprises the sequence 5'-C, G-3' and wherein said MC is less than 10 µm in size.
a polynucleotide comprising an immunostimulatory sequence (ISS) linked to a biodegradable microcarrier (MC), wherein the ISS comprises the sequence 5'-C, G-3' and wherein said MC is less than 10 µm in size.
2. The IMP/MC complex of claim 1, wherein said polynucleotide is covalently linked to said microcarrier.
3. The IMP/MC complex of claim 1, wherein said polynucleotide is non-covalently linked to said microcarrier.
4. The IMP/MC complex of claim 1, wherein said microcarrier is a liquid phase microcarrier.
5. The IMP/MC complex of claim 1, wherein said microcarrier is a solid phase microcarrier.
6. The IMP/MC complex of claim 1, wherein said microcarrier is from 25 nm to 5 µm in size.
7. The IMP/MC complex of claim 6, wherein said microcarrier is from 1.0 ~m to 2.0 µm in size.
8. The IMP/MC complex of claim 7, wherein said microcarrier is 1.4 µm in size.
9. The IMP/MC complex of claim 7, wherein said microcarrier is cationic.
10. The IMP/MC complex of claim 1, wherein said complex is antigen-free.
11. The IMP/MC complex of claim 1, wherein the ISS comprises the sequence 5'-T, C, G-3'.
12. The IMP/MC complex of claim 1, wherein the ISS comprises the sequence 5'-C, G, pyrimidine, pyrimidine, C, G-3'.
13. The IMP/MC complex of claim 1, wherein the ISS comprises the sequence 5'-purine, purine, C, G, pyrimidine, pyrimidine, C, G-3'.
14. The IMP/MC complex of claim 1, wherein the ISS comprises the sequence SEQ
ID NO:1.
ID NO:1.
15. A method of modulating an immune response in an individual comprising administering to an individual an immunomodulatory polynucleotide/microcarrier (IMP/MC) complex, said complex comprising a polynucleotide comprising an immunostimulatory sequence (ISS) linked to a biodegradable microcarrier (MC), wherein the ISS comprises the sequence 5'-C, G-3' and wherein said MC is less than 10 µm in size, in an amount sufficient to modulate an immune response in said individual.
16. The method of claim 15, wherein said microcarrier is a solid phase microcarrier.
17. The method of claim 15, wherein said microcarrier is a liquid phase microcarrier.
18. The method of claim 15, wherein the IMP/MC complex is covalently linked.
19. The method of claim 15, wherein the IMP/MC complex is non-covalently linked.
20. The method of claim 15, wherein said complex is antigen-free.
21. The method of claim 15, wherein a Th1-type immune response is stimulated.
22. The method of claim 15, wherein a Th2-type immune response is suppressed.
23. The method of claim 15, wherein the ISS comprises the sequence 5'-T, C, G-3'.
24. The method of claim 15, wherein the ISS comprises the sequence 5'-C, G, pyrimidine, pyrimidine, C, G-3'.
25. The IMP/MC complex of claim 15, wherein the ISS comprises the sequence 5'-purine, purine, C, G, pyrimidine, pyrimidine, C, G-3'.
26. The IMP/MC complex of claim 15, wherein the ISS comprises the sequence SEQ ID NO:1.
27. A method of increasing interferon-gamma (IFN-.gamma.) in an individual, comprising:
administering an effective amount of an immunomodulatory polynucleotide/microcarrier (IMP/MC) complex to said individual, said complex comprising a polynucleotide comprising an immunostimulatory sequence (ISS) linked to a biodegradable microcarrier (MC), wherein the ISS comprises the sequence 5'-C, G-3', wherein said MC is less than 10 µm in size and wherein an effective amount is an amount sufficient to increase IFN-.gamma. in said individual.
administering an effective amount of an immunomodulatory polynucleotide/microcarrier (IMP/MC) complex to said individual, said complex comprising a polynucleotide comprising an immunostimulatory sequence (ISS) linked to a biodegradable microcarrier (MC), wherein the ISS comprises the sequence 5'-C, G-3', wherein said MC is less than 10 µm in size and wherein an effective amount is an amount sufficient to increase IFN-.gamma. in said individual.
28. The method of claim 27, wherein said microcarrier is a solid phase microcarrier.
29. The method of claim 27, wherein said microcarrier is a liquid phase microcarrier.
30. The method of claim 27, wherein the IMP/MC complex is covalently linked.
31. The method of claim 27, wherein the IMP/MC complex is non-covalently linked.
32. The method of claim 27, wherein said complex is antigen-free.
33. The method of claim 27, wherein the ISS comprises the sequence 5'-T, C, G-3'.
34. The method of claim 27, wherein the ISS comprises the sequence 5'-C, G, pyrimidine, pyrimidine, C, G-3'.
35. The IMP/MC complex of claim 27, wherein the ISS comprises the sequence 5'-purine, purine, C, G, pyrimidine, pyrimidine, C, G-3'.
36. The IMP/MC complex of claim 27, wherein the ISS comprises the sequence SEQ ID NO:1.
37. A method of increasing interferon-alpha (IFN-.alpha.) in an individual, comprising:
administering an effective amount of an immunomodulatory polynucleotide/microcarrier (IMP/MC) complex to said individual, said complex comprising a polynucleotide comprising an immunostimulatory sequence (ISS) linked to a biodegradable microcarrier (MC), wherein the ISS comprises the sequence 5'-C, G-3', wherein said MC is less than 10 µm in size and wherein an effective amount is an amount sufficient to increase IFN-.alpha. in said individual.
administering an effective amount of an immunomodulatory polynucleotide/microcarrier (IMP/MC) complex to said individual, said complex comprising a polynucleotide comprising an immunostimulatory sequence (ISS) linked to a biodegradable microcarrier (MC), wherein the ISS comprises the sequence 5'-C, G-3', wherein said MC is less than 10 µm in size and wherein an effective amount is an amount sufficient to increase IFN-.alpha. in said individual.
38. The method of claim 37, wherein said individual has a viral infection.
39. The method of claim 37, wherein said microcarrier is a solid phase microcarrier.
40. The method of claim 37, wherein said microcarrier is a liquid phase microcarrier.
41. The method of claim 37, wherein the IMP/MC complex is covalently linked.
42. The method of claim 37, wherein the IMP/MC complex is non-covalently linked.
43. The method of claim 37, wherein said complex is antigen-free.
44. The method of claim 37, wherein the ISS comprises the sequence 5'-T, C, G-3'.
45. The method of claim 37, wherein the ISS comprises the sequence 5'-C, G, pyrimidine, pyrimidine, C, G-3'.
46. The IMP/MC complex of claim 37, wherein the ISS comprises the sequence 5'-purine, purine, C, G, pyrimidine, pyrimidine, C, G-3'.
47. The IMP/MC complex of claim 37, wherein the ISS comprises the sequence SEQ ID NO:1.
48. A method of reducing levels of IgE in an individual, comprising:
administering an effective amount of an immunomodulatory polynucleotide/microcarrier (IMP/MC) complex to said individual, said complex comprising a polynucleotide comprising an immunostimulatory sequence (ISS) linked to a biodegradable microcarrier (MC), wherein the ISS comprises the sequence 5'-C, G-3', wherein said MC is less than 10 µm in size and wherein an effective amount is an amount sufficient to reducing levels of IgE in said individual.
administering an effective amount of an immunomodulatory polynucleotide/microcarrier (IMP/MC) complex to said individual, said complex comprising a polynucleotide comprising an immunostimulatory sequence (ISS) linked to a biodegradable microcarrier (MC), wherein the ISS comprises the sequence 5'-C, G-3', wherein said MC is less than 10 µm in size and wherein an effective amount is an amount sufficient to reducing levels of IgE in said individual.
49. The method of claim 48, wherein said microcarrier is a solid phase microcarrier.
50. The method of claim 48, wherein said microcarrier is a liquid phase microcarrier.
51. The method of claim 48, wherein the IMP/MC complex is covalently linked.
52. The method of claim 48, wherein the IMP/MC complex is non-covalently linked.
53. The method of claim 48, wherein said complex is antigen-free.
54. The method of claim 48, wherein the ISS comprises the sequence 5'-T, C, G-3'
55. The method of claim 48, wherein the ISS comprises the sequence 5'-C, G;
pyrimidine, pyrimidine, C, G-3'.
pyrimidine, pyrimidine, C, G-3'.
56. The IMP/MC complex of claim 48, wherein the ISS comprises the sequence 5'-purine, purine, C, G, pyrimidine, pyrimidine, C, G-3'.
57. The IMP/MC complex of claim 48, wherein the ISS comprises the sequence SEQ ID NO:1.
58. A kit, comprising:
a container comprising an immunomodulatory polynucleotide/microcarrier (IMP/MC) complex, wherein the ISS comprises the sequence 5'-C, G-3', wherein said MC
is a biodegradable MC and wherein said MC is less than 10 µm in size; and instructions for use of IMP/MC complex in immunodulation of an individual.
a container comprising an immunomodulatory polynucleotide/microcarrier (IMP/MC) complex, wherein the ISS comprises the sequence 5'-C, G-3', wherein said MC
is a biodegradable MC and wherein said MC is less than 10 µm in size; and instructions for use of IMP/MC complex in immunodulation of an individual.
59. The kit of claim 58, wherein said polynucleotide is covalently linked to said microcarrier.
60. The kit of claim 58, wherein said polynucleotide is non-covalently linked to said microcarrier.
61. The kit of claim 58, wherein said microcarrier is a liquid phase microcarrier.
62. The kit of claim 58, wherein said microcarrier is a solid phase microcarrier.
63. The kit of claim 58, wherein said microcarrier is from 25 nm to 5 µm in size.
64. The kit of claim 63, wherein said microcarrier is from 1.0 µm to 2.0 µm in size.
65. The kit of claim 64, wherein said microcarrier is 1.4 µm in size.
66. The kit of claim 58, wherein said microcarrier is cationic.
67. The kit of claim 58, wherein said complex is antigen-free.
68. The kit of claim 58, wherein the ISS comprises the sequence 5'-T, C, G-3'.
69. The kit of claim 58, wherein the ISS comprises the sequence 5'-C, G, pyrimidine, pyrimidine, C, G-3'.
70. The kit of claim 58, wherein the ISS comprises the sequence 5'-purine, purine, C, G, pyrimidine, pyrimidine, C, G-3'.
71. The kit of claim 58, wherein the ISS comprises the sequence SEQ ID NO:1.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18830300P | 2000-03-10 | 2000-03-10 | |
US60/188,303 | 2000-03-10 | ||
US09/802,359 US20030129251A1 (en) | 2000-03-10 | 2001-03-09 | Biodegradable immunomodulatory formulations and methods for use thereof |
US09/802,359 | 2001-03-09 | ||
PCT/US2001/007848 WO2001068144A2 (en) | 2000-03-10 | 2001-03-12 | Biodegradable immunomodulatory formulations and methods for use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2402247A1 true CA2402247A1 (en) | 2001-09-20 |
CA2402247C CA2402247C (en) | 2011-11-01 |
Family
ID=26883938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2402247A Expired - Fee Related CA2402247C (en) | 2000-03-10 | 2001-03-12 | Biodegradable immunomodulatory formulations and methods for use thereof |
Country Status (8)
Country | Link |
---|---|
US (4) | US20030129251A1 (en) |
EP (1) | EP1261378B1 (en) |
JP (1) | JP2003526682A (en) |
AT (1) | ATE460181T1 (en) |
AU (2) | AU4563101A (en) |
CA (1) | CA2402247C (en) |
DE (1) | DE60141508D1 (en) |
WO (1) | WO2001068144A2 (en) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6727230B1 (en) * | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US7935675B1 (en) * | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
EP0855184A1 (en) * | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US20040006034A1 (en) * | 1998-06-05 | 2004-01-08 | Eyal Raz | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
DE69932717T2 (en) | 1998-05-22 | 2007-08-09 | Ottawa Health Research Institute, Ottawa | METHODS AND PRODUCTS FOR INDUCING MUCOSAL IMMUNITY |
US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
EP1176966B1 (en) * | 1999-04-12 | 2013-04-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Oligodeoxynucleotide and its use to induce an immune response |
US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
US7223398B1 (en) * | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
EP1322655B1 (en) | 2000-01-14 | 2007-11-14 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | Oligodeoxynucleotide and its use to induce an immune response |
AU3108001A (en) * | 2000-01-20 | 2001-12-24 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for inducing a th2 immune response |
US20040131628A1 (en) * | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
US20010046967A1 (en) | 2000-03-10 | 2001-11-29 | Gary Van Nest | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide |
US7129222B2 (en) * | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
US20020098199A1 (en) | 2000-03-10 | 2002-07-25 | Gary Van Nest | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
US7157437B2 (en) | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
CN100334228C (en) | 2001-06-21 | 2007-08-29 | 戴纳瓦克斯技术公司 | Cimeric immunomodulatory compounds and methods of using the same |
US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
WO2003012061A2 (en) * | 2001-08-01 | 2003-02-13 | Coley Pharmaceutical Gmbh | Methods and compositions relating to plasmacytoid dendritic cells |
WO2003014316A2 (en) | 2001-08-07 | 2003-02-20 | Dynavax Technologies Corporation | Immunomodulatory compositions, formulations, and methods for use thereof |
JP2005510462A (en) * | 2001-08-10 | 2005-04-21 | ダイナバックス テクノロジーズ コーポレイション | Production of immunomodulating oligonucleotides and methods of use thereof |
US7354909B2 (en) * | 2001-08-14 | 2008-04-08 | The United States Of America As Represented By Secretary Of The Department Of Health And Human Services | Method for rapid generation of mature dendritic cells |
US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
AU2002366710A1 (en) * | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
CA2388049A1 (en) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7569553B2 (en) * | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
NZ538628A (en) * | 2002-08-12 | 2008-06-30 | Dynavax Tech Corp | Immunomodulatory compositions, methods of making, and methods of use thereof |
AR040996A1 (en) * | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | IMMUNE STIMULATING NUCLEIC ACIDS |
US8263091B2 (en) * | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
MXPA05004588A (en) * | 2002-10-29 | 2005-12-14 | Coley Pharmaceutical Group Ltd | Use of cpg oligonucleotides in the treatment of hepatitis c virus infection. |
AU2003300919A1 (en) | 2002-12-11 | 2004-06-30 | Coley Pharmaceutical Gmbh | 5' cpg nucleic acids and methods of use |
US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
JP2006516099A (en) | 2002-12-23 | 2006-06-22 | ダイナバックス テクノロジーズ コーポレイション | Branched immunomodulatory compounds and methods of using the compounds |
CN100546998C (en) | 2002-12-23 | 2009-10-07 | 戴纳伐克斯技术股份有限公司 | Immunostimulatory sequence oligonucleotides and using method |
US20040235770A1 (en) * | 2003-04-02 | 2004-11-25 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations and related methods of use |
AU2004244962A1 (en) * | 2003-04-10 | 2004-12-16 | 3M Innovative Properties Company | Delivery of immune response modifier compounds using metal-containing particulate support materials |
US20050013812A1 (en) * | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
TWI235440B (en) * | 2004-03-31 | 2005-07-01 | Advanced Semiconductor Eng | Method for making leadless semiconductor package |
CN101160401A (en) * | 2005-02-24 | 2008-04-09 | 科勒制药集团公司 | Immunostimulatory oligonucleotides |
NZ561144A (en) | 2005-03-04 | 2009-09-25 | Dynavax Tech Corp | Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients |
AR054822A1 (en) * | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | ADMISSION IMMUNE EMULSION |
US8703095B2 (en) * | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
FR2888117B1 (en) * | 2005-07-07 | 2009-10-09 | Sanofi Pasteur Sa | VACCINE COMPOSITION COMPRISING A THERMOREVERSIBLE EMULSION |
FR2896162B1 (en) * | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | EMULSION OIL IN THERMOREVERSIBLE WATER |
EP2405002B1 (en) * | 2006-02-15 | 2014-09-24 | AdiuTide Pharmaceuticals GmbH | Compositions and methods for oligonucleotide formulations |
AU2009246169B2 (en) | 2008-05-15 | 2015-01-22 | Dynavax Technologies Corporation | Long term disease modification using immunostimulatory oligonucleotides |
US8552165B2 (en) * | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
PT2376107E (en) | 2008-12-09 | 2014-07-25 | Coley Pharm Group Inc | Immunostimulatory oligonucleotides |
AU2010254549B2 (en) | 2009-05-27 | 2016-10-20 | Selecta Biosciences, Inc. | Nanocarriers possessing components with different rates of release |
KR100998365B1 (en) * | 2009-06-29 | 2010-12-06 | 압타바이오 주식회사 | Novel guanosine rich modified oligonucleotides and antiproliferative activity thereof |
KR101873179B1 (en) | 2009-08-26 | 2018-06-29 | 셀렉타 바이오사이언시즈, 인크. | Compositions that induce t cell help |
MX2012013713A (en) | 2010-05-26 | 2013-01-28 | Selecta Biosciences Inc | Nanocarrier compositions with uncoupled adjuvant. |
US9994443B2 (en) | 2010-11-05 | 2018-06-12 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
US8546550B2 (en) * | 2010-11-16 | 2013-10-01 | Selecta Biosciences, Inc. | Immunostimulatory oligonucleotides |
EA201490381A1 (en) | 2011-07-29 | 2014-06-30 | Селекта Байосайенсиз, Инк. | SYNTHETIC NANOSEAGES WHICH STIMULATE THE FORMATION OF HUMORAL IMMUNE RESPONSE AND IMMUNE RESPONSE MEDIATED BY CYTOTOXIC T-LYMPHOCYTES (CTL) |
US10221230B2 (en) * | 2013-02-25 | 2019-03-05 | Ohio State Innovation Foundation | HER-1, HER-3 and IGF-1R compositions and uses thereof |
CA2902560A1 (en) | 2013-03-14 | 2014-09-25 | President And Fellows Of Harvard College | Nanoparticle-based compositions |
WO2014147131A1 (en) * | 2013-03-19 | 2014-09-25 | Biotech Tools S.A. | Allergen preparation |
CN105579582A (en) | 2013-07-25 | 2016-05-11 | 埃克西奎雷股份有限公司 | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
US10568898B2 (en) | 2013-08-13 | 2020-02-25 | Northwestern University | Lipophilic nanoparticles for drug delivery |
EP3110401A4 (en) | 2014-02-25 | 2017-10-25 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
WO2015168646A1 (en) * | 2014-05-02 | 2015-11-05 | The Research Foundation For The State University Of New York | Compositions and methods for intradermal vaccine delivery |
CA2953216C (en) | 2014-06-04 | 2020-12-22 | Exicure, Inc. | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
US20150374815A1 (en) | 2014-06-25 | 2015-12-31 | Selecta Biosciences, Inc. | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
CA2968531A1 (en) | 2014-11-21 | 2016-05-26 | Northwestern University | The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
CA3012194A1 (en) * | 2016-01-23 | 2017-07-27 | Ampersand Biopharmaceuticals Inc. | Enhanced transdermal delivery of active agents |
WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
KR20190096936A (en) | 2016-09-15 | 2019-08-20 | 이데라 파마슈티칼즈, 인코포레이티드 | Immune Modulation with TLR9 Agonists for Cancer Treatment |
MX2019012385A (en) * | 2017-04-17 | 2022-03-15 | Ampersand Biopharmaceuticals Llc | Parenteral non-systemic administration of buffering agents for inhibiting metastasis of solid tumors, hyperpigmentation and gout. |
WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
US20190083386A1 (en) | 2017-09-15 | 2019-03-21 | Ampersand Biopharmaceuticals, Inc. | Methods and formulations for transdermal administration of buffering agents |
EP3993783A4 (en) * | 2019-07-05 | 2023-07-05 | The Regents of the University of Michigan | Polymer particles for neutrophil injury |
WO2021249116A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Coronavirus vaccine compositions, methods, and uses thereof |
Family Cites Families (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
DE3223104A1 (en) | 1982-06-21 | 1983-12-22 | Hoechst Ag, 6230 Frankfurt | PHOTOPOLYMERIZABLE MIXTURE AND PHOTOPOLYMERIZABLE COPY MATERIAL MADE THEREOF |
US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
US4650675A (en) | 1983-08-18 | 1987-03-17 | The Children's Medical Center Corporation | Oligonucleotide conjugates |
US5015733A (en) | 1983-12-20 | 1991-05-14 | California Institute Of Technology | Nucleosides possessing blocked aliphatic amino groups |
US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
US5118802A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside |
US4849513A (en) | 1983-12-20 | 1989-07-18 | California Institute Of Technology | Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups |
US4828991A (en) | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
US4910300A (en) | 1985-12-11 | 1990-03-20 | Chiron Corporation | Method for making nucleic acid probes |
US5093232A (en) | 1985-12-11 | 1992-03-03 | Chiron Corporation | Nucleic acid probes |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US5124246A (en) | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US5629158A (en) | 1989-03-22 | 1997-05-13 | Cemu Bitecknik Ab | Solid phase diagnosis of medical conditions |
US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
US6465188B1 (en) | 1990-06-11 | 2002-10-15 | Gilead Sciences, Inc. | Nucleic acid ligand complexes |
US5460831A (en) * | 1990-06-22 | 1995-10-24 | The Regents Of The University Of California | Targeted transfection nanoparticles |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
US5770434A (en) | 1990-09-28 | 1998-06-23 | Ixsys Incorporated | Soluble peptides having constrained, secondary conformation in solution and method of making same |
US5849719A (en) | 1993-08-26 | 1998-12-15 | The Regents Of The University Of California | Method for treating allergic lung disease |
AU683957B2 (en) | 1993-11-05 | 1997-11-27 | Amgen, Inc. | Liposome preparation and material encapsulation method |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US7935675B1 (en) * | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
ES2267100T5 (en) | 1994-07-15 | 2011-04-08 | The University Of Iowa Research Foundation | IMMUNOMODULATING OLIGONUCLEOTIDES. |
US5716614A (en) * | 1994-08-05 | 1998-02-10 | Molecular/Structural Biotechnologies, Inc. | Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier |
US5869715A (en) | 1995-09-27 | 1999-02-09 | The Reagents Of The University Of California | Polyfunctional cationic cytofectins |
JP4359654B2 (en) | 1996-01-30 | 2009-11-04 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | Gene expression vector for generating antigen-specific immune response and method of use thereof |
ES2287956T3 (en) | 1996-07-29 | 2007-12-16 | Nanosphere Inc. | NANOPARTICLES THAT HAVE OLIGONUCLEOTIDES UNITED TO THE SAME AND USES OF THE SAME. |
US6610661B1 (en) * | 1996-10-11 | 2003-08-26 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
NZ337054A (en) * | 1997-01-30 | 2001-03-30 | Chiron Corp | Microparticles PLA and PLG with adsorbed viral antigen to stimulate immune responses particularly for intracellular viruses such as HSV-1 or HSV-2, varicella zoster virus. epstein-barr virus or cytomegalovirus (CMV) |
US6884435B1 (en) * | 1997-01-30 | 2005-04-26 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
AU738513B2 (en) | 1997-02-28 | 2001-09-20 | University Of Iowa Research Foundation, The | Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders |
EP1005368B1 (en) | 1997-03-10 | 2009-09-02 | Ottawa Hospital Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants |
US6559129B1 (en) | 1997-03-21 | 2003-05-06 | Georgetown University | Cationic liposomal delivery system and therapeutic use thereof |
EP0983289A4 (en) | 1997-05-19 | 2001-04-25 | Merck & Co Inc | Oligonucleotide adjuvant |
EP1003531B1 (en) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
ATE432348T1 (en) | 1997-06-06 | 2009-06-15 | Univ California | INHIBITORS OF IMMUNO-STIMULATIVE DNA SEQUENCE ACTIVITY |
US6589940B1 (en) * | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
JP4663113B2 (en) | 1997-09-05 | 2011-03-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Use of immunostimulatory oligonucleotides to prevent or reduce antigen-stimulated granulocyte-mediated inflammation |
US7393630B2 (en) * | 1997-12-16 | 2008-07-01 | Novartis Vaccines And Diagnostics, Inc. | Use of microparticles combined with submicron oil-in-water emulsions |
ATE215385T1 (en) * | 1997-12-16 | 2002-04-15 | Chiron Corp | USE OF MICROPARTICLES WITH SUBMICRON OIL/WATER EMULSIONS |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
WO1999051259A2 (en) | 1998-04-03 | 1999-10-14 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
AU3884199A (en) * | 1998-05-06 | 1999-11-23 | Ottawa Health Research Institute | Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides |
US6562798B1 (en) * | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
EP1100807A1 (en) | 1998-07-27 | 2001-05-23 | University Of Iowa Research Foundation | STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS |
IL141687A0 (en) | 1998-09-09 | 2002-03-10 | Scios Inc | Treatment of microvascular angiopathies |
CA2343052A1 (en) * | 1998-09-18 | 2000-03-30 | Dynavax Technologies Corporation | Methods of treating ige-associated disorders and compositions for use therein |
AU6425999A (en) | 1998-10-09 | 2000-05-01 | Dynavax Technologies Corporation | Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens |
WO2000054803A2 (en) | 1999-03-16 | 2000-09-21 | Panacea Pharmaceuticals, Llc | Immunostimulatory nucleic acids and antigens |
EP1176966B1 (en) * | 1999-04-12 | 2013-04-03 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Oligodeoxynucleotide and its use to induce an immune response |
US6977245B2 (en) * | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
GB2355932B (en) | 1999-04-12 | 2004-01-07 | Univ Madras | A pharmaceutical formulation suitable for the treatment of hepatitis B, hepatitis C and other viral infections of the liver and a process for its preparation |
US6558670B1 (en) * | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
PL203951B1 (en) * | 1999-04-19 | 2009-11-30 | Smithkline Beecham Biolog | Vaccines |
AU4978100A (en) | 1999-04-29 | 2000-11-17 | Coley Pharmaceutical Gmbh | Screening for immunostimulatory dna functional modifyers |
GB9915204D0 (en) | 1999-06-29 | 1999-09-01 | Smithkline Beecham Biolog | Vaccine |
US6514948B1 (en) * | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
DE19935302A1 (en) * | 1999-07-28 | 2001-02-08 | Aventis Pharma Gmbh | Conjugates and processes for their preparation and their use for the transport of molecules across biological membranes |
EP1204425B1 (en) * | 1999-08-19 | 2009-01-07 | Dynavax Technologies Corporation | Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
AU780535B2 (en) | 1999-08-27 | 2005-03-24 | Inex Pharmaceuticals Corp. | Compositions for stimulating cytokine secretion and inducing an immune response |
AP2006003503A0 (en) | 1999-09-25 | 2006-02-28 | Univ Iowa Res Found | Immunostimulatory nucleic acids. |
EP1220684B2 (en) | 1999-09-27 | 2010-07-14 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
US7223398B1 (en) * | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
EP1322655B1 (en) | 2000-01-14 | 2007-11-14 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | Oligodeoxynucleotide and its use to induce an immune response |
AT409085B (en) | 2000-01-28 | 2002-05-27 | Cistem Biotechnologies Gmbh | PHARMACEUTICAL COMPOSITION FOR IMMUNULATING AND PRODUCING VACCINES |
US6552006B2 (en) * | 2000-01-31 | 2003-04-22 | The Regents Of The University Of California | Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen |
US6613751B2 (en) * | 2000-02-23 | 2003-09-02 | The Regents Of The University Of California | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
US20010046967A1 (en) * | 2000-03-10 | 2001-11-29 | Gary Van Nest | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide |
US20020107212A1 (en) | 2000-03-10 | 2002-08-08 | Nest Gary Van | Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences |
US7129222B2 (en) * | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
US7157437B2 (en) * | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
US20020028784A1 (en) * | 2000-03-10 | 2002-03-07 | Nest Gary Van | Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences |
US20020098199A1 (en) | 2000-03-10 | 2002-07-25 | Gary Van Nest | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
US20030129251A1 (en) * | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
AU2001249609A1 (en) * | 2000-03-28 | 2001-10-08 | Department Of Veterans Affairs | Methods for increasing a cytotoxic T lymphocyte response in vivo |
AU2001251407A1 (en) | 2000-04-07 | 2001-10-23 | The Regents Of The University Of California | Synergistic improvements to polynucleotide vaccines |
WO2001085910A2 (en) * | 2000-05-05 | 2001-11-15 | The Regents Of The University Of California | Agents that modulate dna-pk activity and methods of use thereof |
US6586503B1 (en) * | 2000-10-18 | 2003-07-01 | Correct Building Products, L.L.C. | Composite products comprising cellulosic materials and synthetic resins and methods of making the same |
DE60142410D1 (en) * | 2000-12-27 | 2010-07-29 | Dynavax Tech Corp | IMMUNOMODULATORY POLYNUCLEOTIDES AND METHOD FOR THE USE THEREOF |
US7785610B2 (en) * | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
CN100334228C (en) * | 2001-06-21 | 2007-08-29 | 戴纳瓦克斯技术公司 | Cimeric immunomodulatory compounds and methods of using the same |
WO2003014316A2 (en) * | 2001-08-07 | 2003-02-20 | Dynavax Technologies Corporation | Immunomodulatory compositions, formulations, and methods for use thereof |
JP2005510462A (en) | 2001-08-10 | 2005-04-21 | ダイナバックス テクノロジーズ コーポレイション | Production of immunomodulating oligonucleotides and methods of use thereof |
US7354909B2 (en) * | 2001-08-14 | 2008-04-08 | The United States Of America As Represented By Secretary Of The Department Of Health And Human Services | Method for rapid generation of mature dendritic cells |
AU2002366710A1 (en) * | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
NZ538628A (en) * | 2002-08-12 | 2008-06-30 | Dynavax Tech Corp | Immunomodulatory compositions, methods of making, and methods of use thereof |
AR040996A1 (en) * | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | IMMUNE STIMULATING NUCLEIC ACIDS |
US7186700B2 (en) * | 2002-09-13 | 2007-03-06 | Idenix Pharmaceuticals, Inc. | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies |
US8043622B2 (en) * | 2002-10-08 | 2011-10-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides |
MXPA05004588A (en) * | 2002-10-29 | 2005-12-14 | Coley Pharmaceutical Group Ltd | Use of cpg oligonucleotides in the treatment of hepatitis c virus infection. |
AU2003300919A1 (en) * | 2002-12-11 | 2004-06-30 | Coley Pharmaceutical Gmbh | 5' cpg nucleic acids and methods of use |
US8158768B2 (en) * | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
JP2006516099A (en) * | 2002-12-23 | 2006-06-22 | ダイナバックス テクノロジーズ コーポレイション | Branched immunomodulatory compounds and methods of using the compounds |
CN100546998C (en) * | 2002-12-23 | 2009-10-07 | 戴纳伐克斯技术股份有限公司 | Immunostimulatory sequence oligonucleotides and using method |
US7387271B2 (en) * | 2002-12-30 | 2008-06-17 | 3M Innovative Properties Company | Immunostimulatory combinations |
US7576068B2 (en) * | 2003-09-05 | 2009-08-18 | Anadys Pharmaceuticals, Inc. | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus |
WO2006066003A2 (en) * | 2004-12-17 | 2006-06-22 | Dynavax Technologies Corporation | Methods and compositions for induction or promotion of immune tolerance |
CA2628424A1 (en) * | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics S.R.L. | Adjuvanted influenza vaccines including cytokine-inducing agents |
DK1957647T3 (en) * | 2005-11-25 | 2015-04-07 | Zoetis Belgium S A | Immunostimulatory oligoribonucleotides |
WO2007130493A2 (en) * | 2006-05-03 | 2007-11-15 | Regents Of The University Of Colorado | Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity |
MX2009003398A (en) * | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity. |
AU2007329375A1 (en) * | 2006-12-04 | 2008-06-12 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to treat cancer with cupredoxins and CpG rich DNA |
EP2207787B1 (en) * | 2007-11-06 | 2014-11-12 | AdiuTide Pharmaceuticals GmbH | Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties |
AU2010254549B2 (en) * | 2009-05-27 | 2016-10-20 | Selecta Biosciences, Inc. | Nanocarriers possessing components with different rates of release |
WO2010138914A1 (en) | 2009-05-29 | 2010-12-02 | Oxonica Materials Inc. | Sers-active particles or substances and uses thereof |
US8546550B2 (en) * | 2010-11-16 | 2013-10-01 | Selecta Biosciences, Inc. | Immunostimulatory oligonucleotides |
-
2001
- 2001-03-09 US US09/802,359 patent/US20030129251A1/en not_active Abandoned
- 2001-03-12 AU AU4563101A patent/AU4563101A/en active Pending
- 2001-03-12 JP JP2001566707A patent/JP2003526682A/en active Pending
- 2001-03-12 EP EP01918571A patent/EP1261378B1/en not_active Expired - Lifetime
- 2001-03-12 AU AU2001245631A patent/AU2001245631B2/en not_active Ceased
- 2001-03-12 DE DE60141508T patent/DE60141508D1/en not_active Expired - Lifetime
- 2001-03-12 AT AT01918571T patent/ATE460181T1/en not_active IP Right Cessation
- 2001-03-12 CA CA2402247A patent/CA2402247C/en not_active Expired - Fee Related
- 2001-03-12 WO PCT/US2001/007848 patent/WO2001068144A2/en active IP Right Grant
- 2001-08-10 US US09/927,422 patent/US7250403B2/en not_active Expired - Lifetime
-
2007
- 2007-06-19 US US11/820,592 patent/US8124590B2/en not_active Expired - Fee Related
-
2012
- 2012-01-25 US US13/358,492 patent/US8669237B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1261378B1 (en) | 2010-03-10 |
US20030022852A1 (en) | 2003-01-30 |
WO2001068144A2 (en) | 2001-09-20 |
ATE460181T1 (en) | 2010-03-15 |
US8669237B2 (en) | 2014-03-11 |
WO2001068144A3 (en) | 2002-05-16 |
CA2402247C (en) | 2011-11-01 |
US7250403B2 (en) | 2007-07-31 |
US8124590B2 (en) | 2012-02-28 |
AU4563101A (en) | 2001-09-24 |
US20120121622A1 (en) | 2012-05-17 |
JP2003526682A (en) | 2003-09-09 |
US20030129251A1 (en) | 2003-07-10 |
US20110038896A1 (en) | 2011-02-17 |
EP1261378A2 (en) | 2002-12-04 |
AU2001245631B2 (en) | 2005-08-25 |
DE60141508D1 (en) | 2010-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2402247A1 (en) | Biodegradable immunomodulatory formulations and methods for use thereof | |
EP1218031B1 (en) | Pharmaceutical composition comprising an antigen | |
CA2380947A1 (en) | Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein | |
WO2001068143A3 (en) | Immunomodulatory formulations and methods for use thereof | |
CA2293470A1 (en) | Benzimidazole derivatives | |
WO1998055495A3 (en) | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof | |
HUP0100197A2 (en) | Compositions and vaccines to enhance an immune response of nucleic acid vaccination | |
TR200100812T2 (en) | Fentanyl composition for the treatment of acute pain. | |
NZ504894A (en) | Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique | |
JP2005500309A5 (en) | ||
CA2291994A1 (en) | Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic acid and their use as antiviral agents | |
BRPI0010612B8 (en) | vaccines | |
BR9808933A (en) | Composition in the form of microcapsules or implants, process for the preparation of a water-soluble substance, active substance, triptorelin acetate, lanreotide acetate, or octreotide acetate, and double-stranded rna | |
FI953442A0 (en) | Freeze-dried beads containing gonadotropin | |
CA2372960A1 (en) | Hiv immunogenic compositions and methods | |
WO2000054730A3 (en) | Compositions preparations and uses of human papillomavirus l1 protein | |
GB9708066D0 (en) | Compositions and their use | |
AP2000001971A0 (en) | Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine. | |
WO2002032378A3 (en) | Fusion cells and cytokine compositions for treatment of disease | |
AU3455093A (en) | New adenosine derivatives, preparation methods and pharmaceutical compositions containing them | |
AU666422B2 (en) | Novel bicyclic pyrimidine compounds, method for preparing same and pharmaceutical compositions containing said compounds | |
BR9508629A (en) | Solvate and hydrate compound of the same processes for the treatment or prophylaxis of a viral infection in a human being and for the preparation of the compound use of a compound and pharmaceutical formulation | |
TR199902733T2 (en) | Pharmaceutical compositions consisting of tizoxanide and nitazoxanide. | |
EP4332225A1 (en) | Application of artificially synthesized cpg single-stranded deoxyoligonucleotide in vaccines | |
FR2682114B1 (en) | SUB-UNIT VACCINE AGAINST NEISSERIA MENINGITIDIS AND SUB-UNITS CORRESPONDING TO PURIFIED STATE. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20180312 |